Advertisement
BIO vs MTD
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Mettler-Toledo International (MTD) Stock Comparison
Key Takeaways
- MTD boasts a significantly larger market capitalization of approximately $26 billion compared to BIO's $7 billion, reflecting greater scale in precision instruments.
- Recent earnings for BIO showed a revenue beat but an EPS (earnings per share) miss, prompting a full-year outlook cut and a sharp stock decline in recent sessions.
- MTD exhibits stronger profitability with a 21.6% profit margin versus BIO's 6.5%, alongside higher return on assets.
- In recent weeks, MTD has displayed modest gains over the past month, contrasting BIO's pullback amid market volatility.
- Analyst price targets suggest upside for both, but MTD holds overweight ratings with a higher average target relative to its price.
Introduction
Bio-Rad Laboratories (BIO) and Mettler-Toledo International (MTD) operate in the scientific instruments and life sciences sector, providing tools for research, diagnostics, and industrial applications. This comparison is relevant for investors seeking exposure to healthcare and precision measurement technologies amid evolving market dynamics, such as funding constraints in research and demand for analytical equipment. Traders monitoring relative performance may find insights into momentum shifts and risk profiles valuable, especially as both stocks navigate earnings seasons and sector rotations in recent market activity.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops products for life sciences research and clinical diagnostics, including instruments, reagents, and software used in genomics, proteomics, and disease testing. In recent market activity, BIO's stock has faced downward pressure, trading around $253 with a 52-week range of $211 to $343 and a P/E ratio (price-to-earnings ratio) of about 9.1. The company recently reported first-quarter 2026 results with revenue of $592 million exceeding estimates but non-GAAP EPS of $1.89 missing expectations, leading to a reduced full-year outlook and a significant share price drop. Sentiment has softened due to tight research funding and process chromatography challenges, contributing to a roughly 10% decline over the past month and negative year-to-date returns.
MTD Overview and Recent Performance
Mettler-Toledo International (MTD) manufactures precision instruments and services for life sciences, industrial, and food retail sectors, including balances, pipettes, and analytical systems. Shares recently traded near $1,266 within a 52-week range of $1,049 to $1,525, supported by a P/E ratio of around 30. In recent weeks, MTD has shown resilience with a modest 1.3% gain over the past month amid broader market fluctuations, though year-to-date returns remain negative. Key influences include anticipation for upcoming first-quarter 2026 earnings and sustained demand in end-markets, with analysts maintaining overweight views despite target adjustments.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots selected from over 351 total bots that trade thousands of tickers across diverse strategies and timeframes. These curated bots, powered by AI and machine learning, adapt to current market conditions with real-time signals, risk management, and styles ranging from trend-following to volatility plays. Performance highlights include annualized returns from +23.67% to +164.21%, win rates of 51% to 88%, and profit factors up to 11.70, often focusing on high-growth sectors like semiconductors and industrials. Traders can explore these for copy trading opportunities tailored to prevailing trends.
Head-to-Head Comparison
Both BIO and MTD serve overlapping life sciences needs but differ in scale and diversification: MTD's broader industrial and food exposure provides revenue stability versus BIO's research-heavy focus vulnerable to funding cycles. Growth drivers for MTD include global demand for precision tools, yielding higher ROA (return on assets) of 20% and margins over 21%, while BIO contends with lower 1.8% ROA and recent EPS volatility. Momentum favors MTD with positive short-term gains and a beta of 1.43 indicating sector sensitivity, against BIO's beta near 0.94 but post-earnings weakness. Risk factors include BIO's higher debt-to-equity and MTD's premium valuation; sentiment leans toward MTD ahead of earnings.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors MTD over BIO, based on superior trend consistency, profitability metrics, and relative stability in recent market positioning. While BIO offers a lower valuation entry, MTD's catalysts like impending earnings and diversified growth prospects indicate higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and MTD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 3 TA indicator(s) are bullish while MTD’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 3 bullish, 7 bearish.
- MTD’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -2.82% price change this week, while MTD (@Medical Specialties) price change was +0.83% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
MTD is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | MTD | BIO / MTD | |
| Capitalization | 7.64B | 23.5B | 33% |
| EBITDA | 440M | 1.25B | 35% |
| Gain YTD | -7.221 | -16.506 | 44% |
| P/E Ratio | 46.77 | 27.34 | 171% |
| Revenue | 2.59B | 4.09B | 63% |
| Total Cash | 1.57B | 60.6M | 2,583% |
| Total Debt | 1.38B | 2.23B | 62% |
BIO | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 2 | |
PRICE GROWTH RATING 1..100 | 52 | 57 | |
P/E GROWTH RATING 1..100 | 13 | 58 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIO's Valuation (83) in the Medical Specialties industry is in the same range as MTD (99). This means that BIO’s stock grew similarly to MTD’s over the last 12 months.
BIO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MTD (100). This means that BIO’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for BIO (90). This means that MTD’s stock grew significantly faster than BIO’s over the last 12 months.
BIO's Price Growth Rating (52) in the Medical Specialties industry is in the same range as MTD (57). This means that BIO’s stock grew similarly to MTD’s over the last 12 months.
BIO's P/E Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for MTD (58). This means that BIO’s stock grew somewhat faster than MTD’s over the last 12 months.
| BIO | MTD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 6 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 61% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 59% |
| Advances ODDS (%) | 8 days ago 66% | 2 days ago 61% |
| Declines ODDS (%) | 2 days ago 68% | 7 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 66% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 63% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.